Skip to main content

Increasing Number of Diagnosed Hemophilia Patients To Drive Bleeding Disorders Treatment Market

The report “Bleeding Disorders Treatment Market by Type Hemophilia A, Hemophilia B, vWD and others, by Drug Class – Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antibrinolytics, Fibrin Sealant and Others – Global Forecast to 2021″, report provides a detailed overview of the major drivers, restraints, threats, opportunities, current market trends, and strategies impacting the bleeding disorders treatment market along with the estimates and forecasts of the revenue and market share analysis.
Browse 36 market data Tables and 20 Figures spread through 170 Pages and in-depth TOC on “Bleeding Disorders Treatment Market by Type Hemophilia A, Hemophilia B, vWD and others, by Drug Class – Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antibrinolytics, Fibrin Sealant and Others – Global Forecast to 2021”.

Early buyers will receive 10% customization on reports.
This report studies the global bleeding disorders treatment market over the forecast period of 2016 to 2021. This market is valued at USD 10.33 Billion in 2016 and expected to grow at a CAGR of 7.9% from 2016 and 2021, to reach an estimated value of USD 15.09 Billion by 2021.


The increasing prevalence of bleeding disorders and their rising awareness are key market drivers. Government initiatives, rising R&D activities, and investments by key players are further expected to expedite the growth of bleeding disorders treatment market globally.

The report segments this market based on type, drug class, and region. The type segment is further classified into hemophilia A, hemophilia B, von Willebrand Disease (vWD), and others. The hemophilia A and B are further classified (based on disease management) as prophylaxis and on-demand. The hemophilia A segment is estimated to account for the largest share in 2015.

The drug class segment is further classified into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants, and others. The recombinant coagulation factor concentrates segment is estimated to account for the largest market share in 2015. Growth in this market is attributed to the rising R&D investments for the development and manufacturing of recombinant products by major players. Plasma-derived segment is estimated to register the slowest CAGR, owing to its reducing demand from end users due to risk of acquiring blood-associated infections. Additionally, difficulty in sourcing plasma from blood (due to scarcity of blood donors) further limits the growth of plasma-derived coagulation factor concentrates market.

Based on region, the global bleeding disorders treatment market is segmented into North America, Europe, Asia-Pacific (APAC), and the Rest of the World (RoW). North America is estimated to contribute the largest share of the market throughout the forecast period. The market in APAC is estimated to register the highest CAGR during the forecast period, owing to increasing awareness of these disorders in the emerging economies such as India and China.

The key players operating in bleeding disorders treatment market include Shire (U.S.), CSL Behring (U.S.), Bayer AG (Germany), Novo Nordisk A/S (Denmark), Pfizer Inc. (U.S.), Biogen (U.S.), and Octapharma (Switzerland).


About MarketsandMarkets™:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “RT” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com

Article Credit: Healthcare DC
Labels:

Comments

Post a Comment

Popular posts from this blog

NGS-Based RNA-Sequencing Industry is Growing at a CAGR of 20%

NGS-based RNA-sequencing Market growth is driven mainly by the advantages of RNA-seq over conventional technologies; an increasing number of RNA-seq grants; rising number of research activities involving RNA-seq; and rapid growth in precision medicine market. NGS-based RNA-sequencing Market: Impact Analysis 1. NGS-Based RNA-Sequencing: Market Overview 2. Geographical Snapshot of the NGS-Based RNA-Sequencing Market 3. Rapid Growth in Precision Medicine 4. Growing Number of Research Activities Involving RNA-Seq 5. Increasing Applications of RNA-Seq in Research ( Cancer and Agricultural) The NGS-based RNA-sequencing market size is estimated to grow from USD 1.7 billion in 2019 to USD 4.2 billion by 2024, at a CAGR of 20.0%. Key Questions Addressed in The Report: 1. Who are the top 10 players operating in the global NGS-based RNA-sequencing market? 2. What are the drivers, restraints, opportunities, and challenges in the NGS-based RNA-sequencing Industry? 3. What are th...
Post a Comment
Read more

Digital Diabetes Management Market to Reach $19.98 billion by 2024 | Market and Regional Growth Analysis

  Digital diabetes management solutions are smartphone-connected diabetes management devices and software platforms used by patients suffering from Type 1, Type 2, and gestational diabetes. Medical professionals also use these solutions to manage diabetes. Various digital diabetes management devices such as smart glucose meters, continuous glucose monitoring systems, smart insulin pens, and smart insulin pumps/closed-loop systems and smart insulin patches are used for glucose monitoring and insulin delivery. Diabetes management applications, data management software & platforms, and services are used by patients and healthcare providers for remote monitoring, data analysis, and disease management. The Digital Diabetes Management Market is experiencing significant growth due to rising prevalence of diabetes has increased the focus on the development and adoption of better solutions for diabetes care. Also, advancements in technologies have ensured the introduction of highly...
Post a Comment
Read more

Epigenetics Market | Major Market Dynamics Impacting The Global Industry

Epigenetics refers to the covalent modification of DNA, RNA, or protein that results in changes to the function and/or regulation of these molecules, without altering their primary sequences. These modifications can occur naturally, or can be influenced, by several factors including age, environment, disease state, and changes in lifestyle. Expanding application areas of epigenetics in non-oncology diseases, personalized medicine, and target therapy are expected to provide growth opportunities for players operating in the epigenetics market in the coming years. The growth in this market is primarily attributed to decreasing sequencing costs, increasing research activity, funding for epigenetics research, rising prevalence of cancer and growing applications of epigenetics in non-oncology diseases. Epigenetic changes such as dysregulation of DNA methylation are associated with cancer development and progression. Epigenetics provides new opportunities for deriving therapeutic strateg...
Post a Comment
Read more